How the US drug safety system should be changed

被引：75

作者：

Strom, BL ^{[1
]}

机构：

[1] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2006年 / 295卷 / 17期

关键词：

D O I：

10.1001/jama.295.17.2072

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2072 / 2075

页数：4

共 19 条

[11] THE NATURE OF ADVERSE EVENTS IN HOSPITALIZED-PATIENTS - RESULTS OF THE HARVARD MEDICAL-PRACTICE STUDY-II [J].

LEAPE, LL ;

BRENNAN, TA ;

LAIRD, N ;

LAWTHERS, AG ;

LOCALIO, AR ;

BARNES, BA ;

HEBERT, L ;

NEWHOUSE, JP ;

WEILER, PC ;

HIATT, H .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (06) :377-384

[12] Changes in isotretinoin prescribing before and after implementation of the System to Manage Accutane Related Teratogenicity™ (SMART™) risk management program [J].

Mendelsohn, AB ;

Governale, L ;

Trontell, A ;

Seligman, P .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2005, 14 (09) :615-618

[13]

*PHRMA, 2004, PHARM IND PROF 2004

[14]

Rawlins JW., 1977, TXB ADVERSE DRUG REA, P44

[15] Promotion of prescription drugs to consumers. [J].

Rosenthal, MB ;

Berndt, ER ;

Donohue, JM ;

Frank, RG ;

Epstein, AM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :498-505

[16] Direct-to-consumer advertising of COX-2 inhibitors: Effect on appropriateness of prescribing [J].

Spence, MM ;

Teleki, SS ;

Cheetham, TC ;

Schweitzer, SO ;

Millares, M .

MEDICAL CARE RESEARCH AND REVIEW, 2005, 62 (05) :544-559

[17]

Strom BL, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P29

[18]

Strom BL, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P219

[19]

*US GEN ACC OFF, 1990, PUBL GAO, P24

← 1 2 →